jaw diseases

Summary

Summary: Diseases involving the JAW.

Top Publications

  1. Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E. Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma. Clin Lab Haematol. 2006;28:393-8 pubmed
    ..The predisposition of MM patients to BON should be further investigated. ..
  2. La Ferla F, Paolicchi E, Crea F, Cei S, Graziani F, Gabriele M, et al. An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. Biomark Med. 2012;6:201-9 pubmed publisher
    ..Recently, genetic polymorphisms have arisen as promising tools to identify patients with a higher risk of drug-related adverse events...
  3. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2010;18:449-60 pubmed publisher
    ..This is a prospective clinical study aimed at assessing the success rate of osteotomy and primary wound closure in patients with bisphosphonate-associated osteonecrosis of the jaw (BONJ)...
  4. Favia G, Pilolli G, Maiorano E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol. 2009;36:2780-7 pubmed publisher
    ..It was postulated that the clinical features, predisposing factors, and treatment outcome of this subset of patients might be different from those of oncologic patients...
  5. Chrcanovic B, Reher P, Sousa A, Harris M. Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors. Oral Maxillofac Surg. 2010;14:3-16 pubmed publisher
    ..Moreover, it is discussed the predisposing and risk factors for the development of osteoradionecrosis based on the literature review...
  6. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, et al. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg. 2010;68:2837-45 pubmed publisher
    ..Therefore, the aim of the present study was to investigate the effects of different bisphosphonate derivatives and dose levels combined with varying pH levels on the mesenchymal stem cells in vitro...
  7. Yamazaki T, Yamori M, Yamamoto K, Saito K, Asai K, Sumi E, et al. Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. Bone. 2012;51:882-7 pubmed publisher
    ..However, oral BPs may increase the risk of OMJ compared with patients treated with other osteoporosis medications and the risk of side effects should be kept in mind...
  8. Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67:2-12 pubmed publisher
  9. Allen M, Burr D. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67:61-70 pubmed publisher

More Information

Publications77

  1. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67:1167-73 pubmed publisher
  2. Park W, Kim N, Kim M, Rhee Y, Kim H. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int. 2010;21:527-33 pubmed publisher
    ..Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can occur irrespective of race. Old age and long-term use of corticosteroid may be a more reliable risk factor than racial characteristics...
  3. Watts N, Diab D. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-65 pubmed publisher
    ..Uncommon side effects have emerged in postapproval use. Because bisphosphonates accumulate in bone and are released for months or years after treatment is stopped, it is reasonable to consider the clinical question of how long to treat...
  4. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxi. J Bone Miner Metab. 2010;28:365-83 pubmed publisher
  5. Patel V, McLeod N, Rogers S, Brennan P. Bisphosphonate osteonecrosis of the jaw--a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg. 2011;49:251-7 pubmed publisher
  6. Hutchinson M, O Ryan F, Chavez V, Lathon P, Sanchez G, Hatcher D, et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010;68:2232-40 pubmed publisher
    ..We sought to characterize radiographic findings in a subgroup of patients with concerning clinical symptoms and bisphosphonate exposure to identify imaging features that may presage development of BRONJ...
  7. Becconsall Ryan K, Tong D, Love R. Radiolucent inflammatory jaw lesions: a twenty-year analysis. Int Endod J. 2010;43:859-65 pubmed publisher
    ..To determine the range and demographic and clinical features of radiolucent inflammatory jaw lesions...
  8. Handschel J, Meyer U. Infection, vascularization, remodelling--are stem cells the answers for bone diseases of the jaws?. Head Face Med. 2011;7:5 pubmed publisher
    ..As the classical pharmacological or surgical treatment protocols have only limited success, stem cells might be a promising treatment option, indicated by recently published data...
  9. Kos M, Brusco D, Kuebler J, Engelke W. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration. Int J Oral Maxillofac Surg. 2010;39:1097-102 pubmed publisher
    ..Bisphosphonates played a role comparable to other predisposing features. Coating the jaws with bisphosphonates could promote the settlement of Actinomyces...
  10. Wehrhan F, Hyckel P, Guentsch A, Nkenke E, Stockmann P, Schlegel K, et al. Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGF?1-signaling and increased Galectin-3 expression: a histological study on biopsies. J Transl Med. 2011;9:102 pubmed publisher
    ..To discriminate between BRONJ-specific impairments in TGF?1 signaling and secondary inflammatory changes, the results were compared to the expression of TGF?1 and Galectin-3 in mucosal tissues with osteoradionecrosis...
  11. Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella R, et al. Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?. J Oral Maxillofac Surg. 2009;67:593-601 pubmed publisher
    ..We report 5 patients with a history of bisphosphonate use, sinus tracts or deep periodontal pockets and radiographic findings typical for BONJ but with no evidence of exposed necrotic bone at the first evaluation visit...
  12. Lesclous P, Abi Najm S, Carrel J, Baroukh B, Lombardi T, Willi J, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?. Bone. 2009;45:843-52 pubmed publisher
    ..We hypothesize that from an initial focus, bone damage spreads centrifugally, both deeper into the jaw and towards the mucosa before the oral bone exposure and the clinical diagnosis of ONJ...
  13. Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente J. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. Am J Otolaryngol. 2009;30:390-5 pubmed publisher
    ..The aim of the present study was to analyze the clinical presentation, risk factors, radiologic features, histopathologic and microbiological findings, treatment, and evolution of bisphosphonate-associated osteonecrosis of the jaws (BONJ)...
  14. Fellows J, Rindal D, Barasch A, Gullion C, Rush W, Pihlstrom D, et al. ONJ in two dental practice-based research network regions. J Dent Res. 2011;90:433-8 pubmed publisher
    ..5 (CI, 6.0-38.7) more likely to have ONJ than non-exposed patients; however, the sparse number of ONJ cases limits firm conclusions and suggests that the absolute risks for ONJ from oral bisphosphonates is low...
  15. Berenson J, Yellin O, Crowley J, Makary A, Gravenor D, Yang H, et al. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. Am J Hematol. 2011;86:25-30 pubmed publisher
    ..Although ONJ and renal deterioration may infrequently occur with ZOL, most patients do not experience worsening of these conditions with ongoing treatment with this bisphosphonate...
  16. Favia G, Pilolli G, Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009;45:406-13 pubmed publisher
    ..No effective treatment has been proposed so far for such lesions, nor is there a uniform concept on the possible pathogenesis of this entity...
  17. Rugani P, Acham S, Truschnegg A, Obermayer Pietsch B, Jakse N. Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:e1-6 pubmed publisher
    ..Stable mucosal coverage could be achieved in all of 5 cases. Laser surgery can be considered as a promising technique for the effective treatment of BRONJ...
  18. Madrid C, Bouferrache K, Abarca M, Jaques B, Broome M. Bisphosphonate-related osteonecrosis of the jaws: how to manage cancer patients. Oral Oncol. 2010;46:468-70 pubmed publisher
    ..The evidence-based literature on BRONJ is growing but there are still many controversial aspects...
  19. Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010;22:404-9 pubmed publisher
    ..The main focus is on bisphosphonates used for osteoporosis...
  20. Skrepnek G, Seal B, Tangirala M, Jeffcoat M, Watts N, Hay J. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent. 2010;58:484-92; quiz 493-4 pubmed
    ..While no significant relationship was observed for oral bisphosphonates, continued research is warranted to assess the long-term use of the medications and adverse events in patients with osteoporosis...
  21. El Gehani R, Orafi M, Elarbi M, Subhashraj K. Benign tumours of orofacial region at Benghazi, Libya: a study of 405 cases. J Craniomaxillofac Surg. 2009;37:370-5 pubmed publisher
    ..The purpose of this study was to systematically analyse the incidence of benign tumours of maxillofacial region within the Libyan population...
  22. Khan A, Sandor G, Dore E, Morrison A, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36:478-90 pubmed publisher
    ..Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention...
  23. Vestergaard P, Schwartz K, Rejnmark L, Mosekilde L, Pinholt E. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. J Oral Maxillofac Surg. 2012;70:821-9 pubmed publisher
    ..The objective of this study was to address whether among people living in Denmark, those treated with medications to prevent osteoporosis have an increased risk for inflammatory jaw disease compared with those not treated...
  24. Lo J, O Ryan F, Gordon N, Yang J, Hui R, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243-53 pubmed publisher
    ..The present study examined the prevalence of ONJ in patients receiving chronic oral bisphosphonate therapy...
  25. Elad S, Gomori M, Ben Ami N, Friedlander Barenboim S, Regev E, Lazarovici T, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. Clin Oral Investig. 2010;14:43-50 pubmed publisher
    ..A large lesion on CT should raise the index of suspicion for sequestrum. The CT appearance of a continuous cortex of the mandibular canal may serve as a differential parameter between BRONJ and metastasis to the jaw...
  26. Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010;25:1668-79 pubmed publisher
    ..These findings provide evidence of an immunity-based mechanism of BRONJ-like disease and support the rationale for in vivo immunomodulatory therapy using Tregs or MSCs to treat BRONJ...
  27. Slootweg P. Lesions of the jaws. Histopathology. 2009;54:401-18 pubmed publisher
    ..Other lesions, not strictly odontogenic but also mainly confined to the jaw bones, are giant cell lesions, fibro-osseous lesions, and the melanotic neuro-ectodermal tumour of infancy. They also will be included in this overview...
  28. Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol. 2007;46:664-8 pubmed
    ..I. 0.4-35.6, p =0.24). The length of exposure to zoledronate was associated with an increased frequency of ONJ in prostate cancer patients. A possible role of chemotherapy with docetaxel as a cofactor for ONJ merits further evaluation. ..
  29. Sedghizadeh P, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler C. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009;140:61-6 pubmed
    ..These findings have important therapeutic and preventive implications. ..
  30. Rizzoli R, Burlet N, Cahall D, Delmas P, Eriksen E, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841-7 pubmed publisher
    ..A majority of ONJ occurs after tooth extraction. Furthermore, the underlying risk of developing ONJ may be increased in osteoporotic patients by comorbid diseases. Treatment for ONJ is generally conservative. ..
  31. Bagan J, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42:327-9 pubmed
  32. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7 pubmed
  33. Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-91 pubmed
    ..Management is largely supportive. A research agenda aimed at filling the considerable gaps in knowledge regarding this disorder was also outlined. ..
  34. Reid I, Bolland M, Grey A. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007;41:318-20 pubmed
  35. Allen M. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs. 2009;189:289-94 pubmed publisher
  36. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904-9 pubmed publisher
    ..Reinitiating bisphosphonates after healing of ONJ is a reasonable option in patients experiencing relapse who are at risk of skeletal complications. Further studies of the pathogenesis and healing of ONJ are needed. ..
  37. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007;18:1363-70 pubmed
    ..Clinicians must be aware of this entity and inform patients of the risks of dental surgery. The synergistic effect of smoking in the pathogenesis of ONJ should be further investigated. ..
  38. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol. 2007;4:711-21 pubmed
    ..A better knowledge of the interactions between BPs and jaw and maxillary bone biology will improve clinical and therapeutic approaches. ..
  39. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-23 pubmed
    ..Appropriate informed consent for the risk of ONJ for different bisphosphonates, for osteoporosis, and malignancy both in general and in particular for dental extractions can be provided using this data. ..
  40. Etminan M, Aminzadeh K, Matthew I, Brophy J. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol. 2008;35:691-5 pubmed
    ..16 (95% CI 0.79-1.70), respectively. In this cohort of elderly cardiovascular patients, an association was observed between oral bisphosphonate use and aseptic osteonecrosis. Further research into this putative association is required. ..
  41. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?. J Oral Maxillofac Surg. 2008;66:1516-7 pubmed publisher
  42. Marx R, Cillo J, Ulloa J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410 pubmed
    ..To assess the risk and time course of oral bisphosphonate-induced osteonecrosis of the jaws...
  43. Dimopoulos M, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos L, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968-71 pubmed
    ..0% and 5%, p=0.003). In conclusion, the risk of ONJ is increased with time of exposure and probably with the use of zoledronic acid...
  44. Pazianas M, Miller P, Blumentals W, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548-58 pubmed
    ..This literature review was performed to elucidate the relationship between bisphosphonate use and development of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates for the treatment of osteoporosis...
  45. Ruggiero S, Drew S. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007;86:1013-21 pubmed
    ..The pathogenesis for this complication appears to be related to the profound inhibition of osteoclast function and bone remodeling...
  46. Boeddinghaus R, Whyte A. Current concepts in maxillofacial imaging. Eur J Radiol. 2008;66:396-418 pubmed
    ..Pre-operative assessment for dental implant placement is also briefly reviewed...
  47. Sedghizadeh P, Kumar S, Gorur A, Schaudinn C, Shuler C, Costerton J. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66:767-75 pubmed publisher
    ..The purpose of this article is to report for the first time the observation of multispecies microbial biofilms on affected bone in patients with osteonecrosis of the jaws (ONJ) secondary to bisphosphonate therapy...
  48. Hall V. Actinomyces--gathering evidence of human colonization and infection. Anaerobe. 2008;14:1-7 pubmed publisher
    ..Diagnosis is commonly belated and based solely upon histological findings. Development of direct detection methods may aid patient management and further elucidate clinical associations...
  49. Durie B, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102; discussion 99-102 pubmed
  50. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634-8 pubmed publisher
    ..The objective of the present study was to determine whether routine dental procedures can be considered as possible risk factors for the development of ONJ in breast cancer patients receiving BP...
  51. Idowu B, Thomas G, Frow R, Diss T, Flanagan A. Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw. Br J Oral Maxillofac Surg. 2008;46:229-30 pubmed
    ..This suggests that cherubism and GCGJ arise on a different genetic background, and therefore detection of SH3BP2 mutations can be a useful means of distinguishing between them...
  52. Hewitt C, Farah C. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med. 2007;36:319-28 pubmed
    ..Bisphosphonate-related osteonecrosis of the jaws (BRONJ) presents the clinician with significant management dilemmas. The purpose of this study was to distil information related to this disorder by comprehensively reviewing the literature...
  53. Wilkinson G, Kuo Y, Freeman J, Goodwin J. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007;99:1016-24 pubmed
    ..We investigated this association by use of data from the Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare claims...
  54. Khan A, Sandor G, Dore E, Morrison A, Alsahli M, Amin F, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008;35:1391-7 pubmed
    ..These guidelines were developed for medical and dental practitioners as well as for oral pathologists and related specialists...
  55. Pazianas M, Blumentals W, Miller P. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. 2008;19:773-9 pubmed
    ..Using jaw surgery as a surrogate marker for osteonecrosis of the jaw, this exploratory study did not find that the risk of jaw surgery was significantly increased with the use of oral bisphosphonates in postmenopausal women...
  56. Raje N, Woo S, Hande K, Yap J, Richardson P, Vallet S, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387-95 pubmed publisher
    ..Osteonecrosis of the jaw (ONJ) has been reported in patients with a history of aminobisphosphonate use. This study was conducted in order to define ONJ clinically and radiographically and gain insights into its pathophysiology...
  57. Malden N, Pai A. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J. 2007;203:93-7 pubmed
    ..However when BONJ is diagnosed, the early application of a closely monitored conservative regimen, with consideration given to discontinuation of the bisphosphonate, may give the best chance of containing or resolving the condition...
  58. Wessel J, Dodson T, Zavras A. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008;66:625-31 pubmed publisher
    ..The aim of the present study was to estimate the magnitude of the association between intravenous (IV) BP exposure and ONJ, and to identify potential confounders...
  59. Madras J, Lapointe H. Keratocystic odontogenic tumour: reclassification of the odontogenic keratocyst from cyst to tumour. J Can Dent Assoc. 2008;74:165-165h pubmed
    ..Future treatment may involve molecular-based modalities, which may reduce or eliminate the need for aggressive surgical management...
  60. Groetz K, Al Nawas B. Persisting alveolar sockets-a radiologic symptom of BP-ONJ?. J Oral Maxillofac Surg. 2006;64:1571-2 pubmed
  61. Van den Wyngaert T, Claeys T, Huizing M, Vermorken J, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20:331-6 pubmed publisher
    ..Overall survival (OS) and outcome of cancer patients with bisphosphonate-associated osteonecrosis of the jaw (ONJ) using conservative treatment (chlorhexidine 0.12% rinse, intermittent antibiotics, and careful sequestrectomy) are unknown...
  62. Zavras A, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?. J Oral Maxillofac Surg. 2006;64:917-23 pubmed
    ..The primary aim of this pilot study was to alert readers to clinically relevant but preliminary information regarding the risk of jaw surgery among patients who received BPs, as compared with patients who did not...
  63. Migliorati C. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:135 pubmed
  64. Lehrer S, Montazem A, Ramanathan L, Pessin Minsley M, Pfail J, Stock R, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:389-91 pubmed publisher
    ..This anatomic concentration of bisphosphonates might cause bisphosphonate-osteonecrosis to be manifested exclusively in the jaws and is consistent with our finding of normal serum bone markers in ONJ patients...
  65. Lima G, Fontes S, de Araujo L, Etges A, Tarquinio S, Gomes A. A survey of oral and maxillofacial biopsies in children: a single-center retrospective study of 20 years in Pelotas-Brazil. J Appl Oral Sci. 2008;16:397-402 pubmed
    ..Most lesions were benign, and malignant lesions were diagnosed in a very small part of the sample...
  66. Buchner A, Merrell P, Carpenter W. Relative frequency of central odontogenic tumors: a study of 1,088 cases from Northern California and comparison to studies from other parts of the world. J Oral Maxillofac Surg. 2006;64:1343-52 pubmed
    ..To determine the relative frequency of central odontogenic tumors in relation to all biopsy specimens and to one another in an oral pathology biopsy service and to compare the data with previous studies from different parts of the world...
  67. Marx R, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-75 pubmed
  68. Boonyapakorn T, Schirmer I, Reichart P, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857-69 pubmed publisher
    ..Neither treatment with high-dose chemotherapy with autologous stem cell transplantation nor treatment with corticosteroids, thalidomide or bortezomib is a risk factor in this study...